Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
SymBiosis Capital Management is a biotechnology venture capital firm located in Arkansas. They focus on investing in bioengineering innovations with potential for industrial scale and speed. The firm has backed 9 companies and emphasizes partnerships with those developing solutions for life-threatening diseases.
SymBiosis invests in biotechnology companies across various modalities, including biologics, cell therapy, genetic medicine, and small molecules. Their investment thesis is agnostic to specific life-threatening diseases, as long as the endpoints for approval are well-established and objective. They target companies with lead candidates that are reaching human proof-of-concept or are expected to do so with their initial investment round.
Notable portfolio companies include: Aardvark Therapeutics, focusing on metabolic disease treatments; AdvanCell, working on scalable targeted alpha therapy for cancer; Aeovian Pharmaceuticals, developing small-molecule therapies for TSC epilepsy; Attivare Therapeutics, offering a modular vaccine platform based on immuno-material technology; Clene Nanomedicine, specializing in nanotherapeutics for neurodegenerative diseases; eGenesis, aiming to address the transplant shortage with human-compatible xenotransplants; Evommune, engaging in novel immunology research through skin; Paradox Immunotherapeutics, developing targeted therapies for protein misfolding diseases; and Tenaya Therapeutics, focusing on curative gene therapies for rare heart diseases.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.